Drug Profile

Research programme: Amyotrophic lateral sclerosis antibody therapeutics - Alchemab Therapeutics/Eli Lilly

Latest Information Update: 10 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

10 Feb 2025 QC feedbacks incorporated
09 Jan 2025 Alchemab Therapeutics and Eli Lilly agree to co-develop Amyotrophic lateral sclerosis (ALS) targeting antibodies for Amyotrophic lateral sclerosis (ALS)
09 Jan 2025 Early research in Amyotrophic lateral sclerosis in United Kingdom (Parenteral)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com